Literature DB >> 33332576

COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.

Erhan Ayhan1, Murat Öztürk2, İsa An3, Muhammed Bekçİbaşi4.   

Abstract

Entities:  

Year:  2020        PMID： 33332576     DOI： 10.1111/ijd.15379

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  4 in total

1.  The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment.

Authors:  Emel Atayik; Gokhan Aytekin
Journal:  Rev Fr Allergol (2009)       Date:  2022-06-13

2.  Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.

Authors:  Maria Passante; Maddalena Napolitano; Stefano Dastoli; Luigi Bennardo; Gabriella Fabbrocini; Steven Paul Nisticò; Cataldo Patruno
Journal:  Dermatol Ther       Date:  2021-08-31       Impact factor: 3.858

Review 3.  Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.

Authors:  Dimitri Poddighe; Elena Kovzel
Journal:  J Inflamm Res       Date:  2021-12-14

4.  The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.

Authors:  Ecem Bostan; Fethi Zaid; Aysen Karaduman; Sibel Dogan; Duygu Gulseren; Basak Yalici-Armagan; Neslihan Akdogan; Sibel Ersoy-Evans; Gonca Elcin
Journal:  J Cosmet Dermatol       Date:  2021-10-02       Impact factor: 2.696
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.